0001645113-23-000025.txt : 20230302 0001645113-23-000025.hdr.sgml : 20230302 20230302164932 ACCESSION NUMBER: 0001645113-23-000025 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230228 FILED AS OF DATE: 20230302 DATE AS OF CHANGE: 20230302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GROENHUYSEN WILHELMUS CM CENTRAL INDEX KEY: 0001264783 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 23699878 MAIL ADDRESS: STREET 1: C/O NAVTEQ CORPORATION STREET 2: 222 MERCHANDISE MART STE 900 CITY: CHICAGO STATE: IL ZIP: 60654 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 4 1 wf-form4_167779374758834.xml FORM 4 X0306 4 2023-02-28 0 0001645113 NovoCure Ltd NVCR 0001264783 GROENHUYSEN WILHELMUS CM C/O NOVOCURE INC., 1550 LIBERTY RIDGE DRIVE, SUITE 115 WAYNE PA 19087 0 1 0 0 Chief Operating Officer Ordinary Shares 2023-02-28 4 A 0 21653 0 A 186779 D Ordinary Shares 2023-03-01 4 S 0 2164 76.3624 D 184615 D Options to Buy Ordinary Shares 76.97 2023-02-28 4 A 0 36013 76.97 A 2024-02-28 2033-02-27 Ordinary Shares 36013.0 36013 D Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Options to buy 36,013 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. By: /s/ Steven Robbins, Attorney in Fact for Wilhelmus CM Groenhuysen 2023-03-02